{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:49:44Z","timestamp":1791596984327,"version":"4.3.4"},"reference-count":53,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001047","name":"Ian Potter Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.isci.2026.117321","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:33:08Z","timestamp":1787851988000},"page":"117321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-inflammatory and phosphorylation effects of CFTR modulator triple therapy in cystic fibrosis"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0515-0051","authenticated-orcid":false,"given":"Hiran","family":"Selvadurai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velda X.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke A.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Aryamanesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee L.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suat","family":"Dervish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhong","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruwani","family":"Dissanayake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen I.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrujna","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell C.","family":"Dale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.117321_bib1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","article-title":"Cystic fibrosis","volume":"10","author":"Mall","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.isci.2026.117321_bib2","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117321_bib3","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.isci.2026.117321_bib4","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1056\/NEJMra043184","article-title":"Cystic Fibrosis","volume":"352","author":"Rowe","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117321_bib5","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/354526a0","article-title":"Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation","volume":"354","author":"Dalemans","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117321_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fchem.2016.00001","article-title":"Regulatory Crosstalk by Protein Kinases on CFTR Trafficking and Activity","volume":"4","author":"Farinha","year":"2016","journal-title":"Front. Chem."},{"key":"10.1016\/j.isci.2026.117321_bib7","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine","volume":"10","author":"Lopes-Pacheco","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.isci.2026.117321_bib8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1126\/science.ade2216","article-title":"Molecular structures reveal synergistic rescue of \u0394508 CFTR by Trikafta modulators","volume":"378","author":"Fiedorczuk","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.117321_bib9","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02029-2022","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study","volume":"62","author":"Daines","year":"2023","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.isci.2026.117321_bib10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1164\/rccm.202301-0021OC","article-title":"Long-Term Safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in Children Aged \u2a7e6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial","volume":"208","author":"Wainwright","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.isci.2026.117321_bib11","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and Safety of Elexacaftor\/Tezacaftor\/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study","volume":"206","author":"Mall","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.isci.2026.117321_bib12","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A Phase 3 Open-Label Study of Elexacaftor\/Tezacaftor\/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.isci.2026.117321_bib13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 Open-Label Clinical Trial of Elexacaftor\/Tezacaftor\/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.isci.2026.117321_bib14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/ajrccm\/aamaf001","article-title":"Elexacaftor\/tezacaftor\/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and real-world study","volume":"212","author":"Castellani","year":"2026","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.isci.2026.117321_bib15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcf.2023.12.002","article-title":"Standards for the care of people with cystic fibrosis; establishing and maintaining health","volume":"23","author":"Southern","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.isci.2026.117321_bib16","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1055\/s-0039-1697975","article-title":"Acute Pulmonary Exacerbations in Cystic Fibrosis","volume":"40","author":"Goss","year":"2019","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.isci.2026.117321_bib17","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.biocel.2014.01.017","article-title":"Current concepts of immune dysregulation in cystic fibrosis","volume":"52","author":"Rieber","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.isci.2026.117321_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adk9145","article-title":"Perinatal dysfunction of innate immunity in cystic fibrosis","volume":"17","author":"Jaudas","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2026.117321_bib19","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1165\/rcmb.2011-0399RT","article-title":"Immune responses in cystic fibrosis: are they intrinsically defective?","volume":"46","author":"Ratner","year":"2012","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.isci.2026.117321_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e17553","article-title":"Role of innate immunity and systemic inflammation in cystic fibrosis disease progression","volume":"9","author":"Purushothaman","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.isci.2026.117321_bib21","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/408935","article-title":"Free DNA in cystic fibrosis airway fluids correlates with airflow obstruction","volume":"2015","author":"Marcos","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.isci.2026.117321_bib22","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1165\/rcmb.2019-0032OC","article-title":"Transcriptomic Responses to Ivacaftor and Prediction of Ivacaftor Clinical Responsiveness","volume":"61","author":"Sun","year":"2019","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.isci.2026.117321_bib23","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jcf.2019.08.021","article-title":"Whole-blood transcriptomic responses to lumacaftor\/ivacaftor therapy in cystic fibrosis","volume":"19","author":"Kopp","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.isci.2026.117321_bib24","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1164\/rccm.202106-1426OC","article-title":"Trikafta Rescues CFTR and Lowers Monocyte P2X7R-induced Inflammasome Activation in Cystic Fibrosis","volume":"205","author":"Gabillard-Lefort","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.isci.2026.117321_bib25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12931-026-03494-9","article-title":"Modulation of immune responses by elexacaftor\/tezacaftor\/ivacaftor therapy in cystic fibrosis: data from a compassionate use program","volume":"27","author":"Lucca","year":"2026","journal-title":"Respir. Res."},{"key":"10.1016\/j.isci.2026.117321_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0304555","article-title":"Anti-inflammatory effects of elexacaftor\/tezacaftor\/ivacaftor in adults with cystic fibrosis heterozygous for F508del","volume":"19","author":"Jarosz-Griffiths","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2026.117321_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1486784","article-title":"Proteomics profiling of inflammatory responses to elexacaftor\/tezacaftor\/ivacaftor in cystic fibrosis","volume":"16","author":"Ozuna","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117321_bib28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1513\/AnnalsATS.202507-817OC","article-title":"Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"23","author":"Sagel","year":"2026","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.isci.2026.117321_bib29","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00150-2025","article-title":"Reduction of systemic inflammation by elexacaftor\/tezacaftor\/ivacaftor correlates with lung function improvement in cystic fibrosis","volume":"66","author":"Halle","year":"2025","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.isci.2026.117321_bib30","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/thorax-2022-219943","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on airway and systemic inflammation in cystic fibrosis","volume":"78","author":"Casey","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.isci.2026.117321_bib31","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.3892\/mmr.2020.11607","article-title":"Research advances in molecular mechanisms underlying the pathogenesis of cystic fibrosis: From technical improvement to clinical applications (Review)","volume":"22","author":"Wei","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.isci.2026.117321_bib32","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/jleuko\/qiad139","article-title":"Aberrant immune programming in neutrophils in cystic fibrosis","volume":"115","author":"Hu","year":"2024","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.isci.2026.117321_bib33","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/14728222.2018.1501361","article-title":"The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease","volume":"22","author":"Moore","year":"2018","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.isci.2026.117321_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/cells10112844","article-title":"CFTR Protein: Not Just a Chloride Channel?","volume":"10","author":"Hanssens","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.isci.2026.117321_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005221","article-title":"An Asymmetrically Balanced Organization of Kinases versus Phosphatases across Eukaryotes Determines Their Distinct Impacts","volume":"13","author":"Smoly","year":"2017","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.isci.2026.117321_bib36","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/978-1-61779-117-8_29","article-title":"CFTR regulation by phosphorylation","volume":"741","author":"Alzamora","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.isci.2026.117321_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.690247","article-title":"Role of Protein Kinase A-Mediated Phosphorylation in CFTR Channel Activity Regulation","volume":"12","author":"Della Sala","year":"2021","journal-title":"Front. Physiol."},{"key":"10.1016\/j.isci.2026.117321_bib38","doi-asserted-by":"crossref","first-page":"L770","DOI":"10.1152\/ajplung.00262.2019","article-title":"G551D mutation impairs PKA-dependent activation of CFTR channel that can be restored by novel GOF mutations","volume":"319","author":"Wang","year":"2020","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.isci.2026.117321_bib39","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1469-7793.2000.00637.x","article-title":"Deletion of phenylalanine 508 causes attenuated phosphorylation-dependent activation of CFTR chloride channels","volume":"524","author":"Wang","year":"2000","journal-title":"J. Physiol."},{"key":"10.1016\/j.isci.2026.117321_bib40","doi-asserted-by":"crossref","first-page":"36639","DOI":"10.1074\/jbc.M112.393637","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner","volume":"287","author":"Eckford","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.isci.2026.117321_bib41","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2026.117321_bib44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.isci.2026.117321_bib47","series-title":"R: A Language and Environment for Statistical Computing","year":"2013"},{"key":"10.1016\/j.isci.2026.117321_bib48","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the Tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J. Open Source Softw."},{"key":"10.1016\/j.isci.2026.117321_bib49","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/nbt.2931","article-title":"Normalization of RNA-seq data using factor analysis of control genes or samples","volume":"32","author":"Risso","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2026.117321_bib50","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.isci.2026.117321_bib51","series-title":"ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2016"},{"key":"10.1016\/j.isci.2026.117321_bib52","series-title":"pheatmap: Pretty Heatmaps (R package version 1.0.13)","author":"Kolde","year":"2025"},{"key":"10.1016\/j.isci.2026.117321_bib53","series-title":"enrichplot: Visualization of Functional Enrichment Result. R package version 1.33.0, [Bioconductor enrichplot]","author":"Yu","year":"2026"},{"key":"10.1016\/j.isci.2026.117321_bib42","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.isci.2026.117321_bib43","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1183\/09031936.00069712","article-title":"Consensus statement for inert gas washout measurement using multiple- and single- breath tests","volume":"41","author":"Robinson","year":"2013","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.isci.2026.117321_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105156","article-title":"Ketogenic diet modifies ribosomal protein dysregulation in KMT2D Kabuki syndrome","volume":"104","author":"Tsang","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.isci.2026.117321_bib46","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/brain\/awae254","article-title":"Proteostasis as a fundamental principle of Tau immunotherapy","volume":"148","author":"Cruz","year":"2025","journal-title":"Brain"}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226026994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226026994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:58:17Z","timestamp":1791593897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226026994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2589004226026994"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.117321","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-inflammatory and phosphorylation effects of CFTR modulator triple therapy in cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.117321","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117321"}}